News

Prostate Cancer Pipeline Outlook Report 2025: Key 140+ Companies And Breakthrough Therapies Shaping The Future Landscape

In July 2025, Merck Sharp & Dohme LLC announced a substudy is to assess the efficacy and safety of ifinatamab deruxtecan ...